Day-by-day guide to ASCO

1-5 June 2007

McCormick Place
Chicago, IL, USA
Contents

Congress details 2
Dining 3
Safety 4
Congress site plan 6
Key 11
Saturday 2 June 12
Sunday 3 June 19
Monday 4 June 24
Tuesday 5 June 28
Hotels 30
Map 31
Congress details

Congress venue
McCormick Place
2301 South Lake Shore Drive
Chicago, IL 60616, USA
Tel: 312 791 7000; Fax: 312 791 6543

Congress registration
Location: McCormick Place
Friday 1 June: Onsite registration opens (including self-registration)
Tuesday 5 June: Onsite registration closes

Congress dates and opening hours
Friday 1 June 13:00-18:00
Saturday 2 June 07:30-18:00
Sunday 3 June 07:30-18:00
Monday 4 June 07:30-18:00
Tuesday 5 June 07:30-12:45
Recommended restaurants

Aria (American Contemporary with International Flair)
200 North Columbus Drive, Chicago, IL 60601
Tel: 312 444 9494

Bandera (American Contemporary)
535 North Michigan Avenue, Chicago, IL 60611
Tel: 312 644 3524

Catch 35 (Seafood)
35 West Wacker Drive, Chicago, IL 60601
Tel: 312 346 3500

China Grill (Pan-Asian)
230 North Michigan Avenue, Chicago, IL 60601
Tel: 312 334 6700

Kevin (French Fusion)
9 West Hubbard Street, Chicago, IL 60610
Tel: 312 595 0055

McCormick & Schmick’s (Seafood)
1 East Wacker Drive, Chicago, IL 60601
Tel: 312 923 7226

Morton’s (Steak and Seafood)
65 East Wacker Place, Chicago, IL 60601
Tel: 312 201 0410

Phil Stefani’s 437 Rush (Italian Steakhouse)
437 North Rush Street, Chicago, IL 60611
Tel: 312 222 0101

Shula’s Steakhouse (Steak and Seafood)
301 East North Water Street, Chicago, IL 60611
Tel: 312 670 0788

The Palm (Steak, Seafood and Italian)
323 East Wacker Drive, Chicago IL 60601
Tel: 312 616 1000

Vermilion (Indian/Latin Fusion)
10 West Hubbard Street, Chicago, IL 60610
Tel: 312 527 4060

Volare (Italian)
201 East Grand Avenue, Chicago, IL 60611
Tel: 312 419 9800
Safety

Safety tips
On leaving the congress site you are advised to remove your ASCO name badge or any Roche identity insignia.

Keep jewellery or accessories to a minimum and do not display cameras or bags that can draw attention.

Keep your wallet or precious belongings in your inside front pocket or wear your handbag across your shoulders.

Sightsee on well-lit, well-travelled streets and passages either with a colleague or in a group.

Important telephone numbers
Emergency services (Police, Ambulance, Fire): 911
Non-emergency services (Police and City Services): 311
Yellow Cab Chicago: 312 8294 222
Chicago Office of Tourism: 312 744 2400
Congress site plan

[Diagram of Congress site plan]
Key to symbols used throughout the planner

- A Avastin
- B Bondronat
- H Herceptin
- M MabThera
- T Tarceva
- X Xeloda
POSTER DISCUSSION SESSION
Time: 08:00-12:00 [discussion 12:00-13:00]
Venue: S403 [S406 Vista Room]

Breast cancer - metastatic

HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients (U Wilking; Poster 10, Abstract 1023)

A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer (MBC) (B Sherrill; Poster 13, Abstract 1026)

A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC) (M Stockler; Poster 18, Abstract 1031)

Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data (CE Geyer; Poster 22, Abstract 1035)

GENERAL POSTER SESSION
Time: 08:00-12:00
Venue: S Hall A2

Health services research

Cost-effectiveness of rituximab plus CVP for first-line treatment of advanced indolent lymphoma (J Hornberger; Poster D13, Abstract 6583)

The utilization of new oncology drugs: A global perspective (B Jönsson; Poster F14, Abstract 6612)

Cost-effectiveness (CE) analysis of CHOP and rituximab for diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC) (GW Loh; Poster G11, Abstract 6623)
GENERAL POSTER SESSION
Time: 08:00-12:00
Venue: S Hall A2

Lymphoma and plasma cell disorders

Rituximab maintenance therapy (RM) for relapsed/refractory follicular lymphoma (FL): Long-term economic impact in the French setting (P Brice; Poster X5, Abstract 8076)

A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma (L Yee; Poster X7, Abstract 8078)

Cost-effectiveness of rituximab maintenance therapy for patients with follicular lymphoma: The Spanish perspective (J Gómez Codina; Poster Z7, Abstract 8092)

ORAL ABSTRACT PRESENTATION SESSION
Time: 13:00-16:00
Venue: E Arie Crown Theater

Leukemia, myelodysplasia and transplantation

Seventy percent of complete responders remain in continuous remission: Five-year follow-up of 300 patients treated with fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy of CLL (CS Tam; Abstract 7008)

Time: 14:15-14:30

Salvage therapy following failure or relapse after FCR chemo-immunotherapy as initial treatment for chronic lymphocytic leukemia (CLL) (MJ Keating; Abstract 7009)

Time: 14:30-14:45
ORAL ABSTRACT PRESENTATION SESSION

Time: 13:00-16:00
Venue: N Hall B1

Lung cancer I

Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 (C Manegold; Abstract LBA7514)

Time: 14:45-15:00

GENERAL POSTER SESSION

Time: 14:00-18:00
Venue: S Hall A2

Breast cancer – local-regional and adjuvant therapy

Inflammatory and locally advanced breast cancer respond similar to operable breast cancer to neoadjuvant chemotherapy; Results from 278 patients with cT4a-d tumors of the GeparTRIO trial (G Von Minckwitz; Poster A1, Abstract 542)

Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study (JE Lester; Poster A12, Abstract 553)

A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer (EL Mayer; Poster B6, Abstract 561)

Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety (MN Dickler; Poster B12, Abstract 567)
A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer (LA Kutteh; Poster C10, Abstract 379)

Pathologic complete response (pCR) following weekly (wkly) paclitaxel (cremophor or albumin-bound) and carboplatin (TC) ± trastuzumab (H), ± bevacizumab (B) in patients (pts) with doxorubicin/cyclophosphamide-resistant (AC-Res) and AC-sensitive (AC-S) large and inflammatory breast cancer (RS Mehta; Poster D8, Abstract 591)

**GENERAL POSTER SESSION**

**Breast cancer - metastatic**

Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995 (Z Neskovic-Konstantinovic; Poster G2, Abstract 1040)

A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) (M Beeram; Poster G4, Abstract 1042)

Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model (TA Traina; Poster G11, Abstract 1049)

Efficacy of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination (NVBoXH) in HER2-positive metastatic breast cancer (MBC); First results of an international phase II trial (A Chan; Poster G14, Abstract 1052)
Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC) (SG Bradley; Poster H1, Abstract 1053)

Trastuzumab (T) plus capecitabine (C) in heavily pretreated patients (pts) with advanced breast cancer (ABC) (R Bartsch; Poster H3, Abstract 1055)

Chemoprotection by VEGF: Rationale for combination nab-paclitaxel and bevacizumab (V Trieu; Poster H12, Abstract 1064)

Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC) (G Metro; Poster H14, Abstract 1066)

Clodronate compared to ibandronate breast cancer bone metastases patient preference study (S Jagdev; Poster J2, Abstract 1068)

Inter- and intra-country variations in the use of trastuzumab in Norway, Spain and Sweden (N Wilking; Poster J3, Abstract 1069)

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer (MBC) patients in Sweden (M Lidgren; Poster L8; Abstract 1088)

Capecitabine (X) monotherapy as first-line chemotherapy (CT) for metastatic breast cancer (MBC); High efficacy regardless of prior therapy (L Mauriac; Poster M1, Abstract 1092)

Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression (T Bachelot; Poster M3, Abstract 1094)

Administration of further chemotherapy (CT) after capecitabine as first-line chemotherapy (CT) for metastatic breast cancer (MBC) (M Debled; Poster M4, Abstract 1095)
Efficacy of i.v. and oral ibandronate in bone metastases breast cancer patients and some clinical aspects of bisphosphonates studies: Clinical experience of one trial center (M Lichinitser; Poster M5, Abstract 1096)

A retrospective review of breast cancer patients with central nervous system metastasis treated with capecitabine (M Kurt; Poster M7, Abstract 1098)

Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer (JS Link; Poster M10, Abstract 1101)

Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report (AK Conlin; Poster N2, Abstract 1104)

Renal safety of intravenous ibandronate 6mg infused over 15 or 60 minutes in patients with breast cancer and bone metastases: A randomized, open-label study (R von Moos; Poster P1, Abstract 1114)

POSTER DISCUSSION SESSION

Time: 14:00-18:00 [discussion 17:00-18:00]
Venue: S403 [S406 Vista Room]

Gastrointestinal (colorectal) cancer

Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (L Saltz; Poster 15, Abstract 4028)

Comparable safety and response rate with bevacizumab in combination with capcitabine/oxaliplatin (CapOxz/Bev) versus capcitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group (WH Schmiegel; Poster 21, Abstract 4034)
Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE) (A Grothey; Poster 23, Abstract 4036)

**ORAL ABSTRACT PRESENTATION SESSION**

**Time:** 15:00-18:15  
**Venue:** E Hall D2

**Head and neck cancer**

Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer (ES Kim; Abstract 6013)  
**Time:** 17:30-17:45

**CLINICAL SCIENCE SYMPOSIUM**

**Time:** 16:30-18:00  
**Venue:** N Hall B1

**Targeting breast cancer with monoclonal antibodies and small molecules: beyond HER2**

Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T (J Baselga; Abstract 1004)  
**Time:** 17:30-17:45
GENERAL POSTER SESSION
Time: 08:00-12:00
Venue: S Hall A2

Developmental therapeutics: immunotherapy
Lumiliximab (anti-CD23 antibody) mediates apoptosis and antitumor activity in chronic lymphocytic leukemia (CLL) cells and CD23+ lymphoma cell lines (N Pathan; Poster E5, Abstract 3039)

Developmental therapeutics: molecular therapeutics
A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies (SK Chia; Poster M2, Abstract 3594)

Lung cancer
Phase II study of erlotinib in chemo-naive women with advanced pulmonary adenocarcinoma (D Jackman; Poster P5, Abstract 7591)
Skin rash as surrogate marker of efficacy in patients with non-small cell lung cancer treated with erlotinib (M Cobo; Poster Q5, Abstract 7602)
Correlation of the EGFR gene mutation, gene amplification and protein expression in non-small cell lung cancer with clinical outcomes of erlotinib monotherapy: An exploratory analysis of biomarkers by the Korean Cancer Study Group (M-J Ahn; Poster Q11, Abstract 7608)
A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC) (HJ Groen; Poster S6, Abstract 7625)

Erlotinib for first line treatment in unselected patients (p) with advanced or metastatic non-small cell lung carcinoma (NSCLC) (U Jimenez; Poster T9, Abstract 7639)

Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study (U Gatzemeier; Poster U4, Abstract 7645)

Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC) (J Carlson; Poster X1, Abstract 7664)

Biomarker analysis from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC) (C-P Schneider; Poster Y3, Abstract 7674)

Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC) (TJ Lynch; Poster Z1, Abstract 7680)

ORAL ABSTRACT PRESENTATION SESSION

Time: 09:00-12:00
Venue: N Hall B1

Breast cancer – metastatic

Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes (LT Vahdat; Abstract 1006)

Time: 09:15-09:30
BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) (MD Pegram; Abstract LBA1008)
Time: 09:45-10:00

Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer (G Sledge; Abstract 1013)
Time: 11:30-11:45

**ORAL ABSTRACT PRESENTATION SESSION**
Time: 09:30-12:30
Venue: E354b

**Lymphoma**

Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy (M Federico; Abstract 8008)
Time: 09:30-09:45

Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients (B Coiffier; Abstract 8009)
Time: 09:45-10:00

Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LN98-B3 GELA study (C Haioun; Abstract 8012)
Time: 10:45-11:00
Sunday

3 June

ORAL ABSTRACT PRESENTATION SESSION
Time: 13:00-16:00
Venue: E354b

Myeloma

Long-term responses to thalidomide and rituximab in Waldenstrom’s macroglobulinemia (JD Soumerai; Abstract 8017)
Time: 13:00-13:15

GENERAL POSTER SESSION
Time: 14:00-18:00
Venue: S Hall A2

Pediatric cancer

ITCC phase I study of erlotinib as single agent in children with refractory and relapsed malignant brain tumors and in combination with irradiation in newly diagnosed brain stem glioma (B Georger; Poster Z8, Abstract 9556)

POSTER DISCUSSION SESSION
Time: 14:00-18:00 [discussion 17:00-18:00]
Venue: S403 [S406 Vista Room]

Breast cancer – local-regional and adjuvant therapy

Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis (L Gianni; Poster 12, Abstract 532)

POSTER DISCUSSION SESSION
Time: 14:00-18:00 [discussion 17:00-18:00]
Venue: S102a [S100b]

Developmental therapeutics: immunotherapy

A phase II trial of trastuzumab and low dose interleukin-2 in patients with metastatic breast cancer who have previously failed trastuzumab (A Mani; Poster 19, Abstract 3028)
CLINICAL SCIENCE SYMPOSIUM

Time: 16:30-18:00
Venue: E354b

Improving survival in follicular lymphoma: integrating new therapy

Prospective, multicenter, randomized GITMO-IIL trial comparing intensive (R-HDS) to conventional chemoimmunotherapy (CHOP-R) in high-risk follicular lymphoma (FL) at diagnosis (M Ladetto; Abstract 8006)

Time: 17:30-17:45
GENERAL POSTER SESSION

Time: 08:00-12:00
Venue: S Hall A2

Gastrointestinal (colorectal) cancer

- Phase I/II study of neoadjuvant bevacizumab with radiation therapy and 5-fluorouracil in patients with rectal cancer: initial results (C Willett; Poster A3, Abstract 4041)

- Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with resectable colorectal cancer liver metastases (B Gruenberger; Poster D1, Abstract 4060)

- Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer (T Gruenberger; Poster D5, Abstract 4064)

- Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI (AF Sobrero; Poster E2, Abstract 4068)

- Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial (A Kretzschmar; Poster E6, Abstract 4072)

- Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bevacizumab (BV) in combination with oxaliplatin-containing regimens: An analysis of two phase III studies (BJ Giantonio; Poster E7, Abstract 4073)

- A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (mCRC): XELOX vs. FOLFOX4 ± bevacizumab (A) (W Scheithauer; Poster J4, Abstract 4098)
GENERAL POSTER SESSION
Time: 08:00-12:00
Venue: S Hall A2

Gastrointestinal (noncolorectal) cancer
A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer
(C Gomez-Martin; Poster BB2, Abstract 4611)

POSTER DISCUSSION SESSION
Time: 08:00-12:00 [discussion 11:00-12:00]
Venue: E451a [E354b]

Leukemia, myelodysplasia and transplantation
Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) (AM Tsimberidou; Poster 22, Abstract 7034)

ORAL ABSTRACT PRESENTATION SESSION
Time: 09:00-12:00
Venue: E Hall D1

Breast cancer – local-regional and adjuvant therapy
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (E Perez; Abstract 512)
Time: 09:00-09:15

Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC→T with trastuzumab (H) (P Rastogi; Abstract LBA513)
Time: 09:15-09:30
Monday

4 June

SPECIAL SESSION
Time: 13:00-16:00
Venue: N Hall B1

Monday plenary session

A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma (B Escudier; Abstract 3)
Time: 14:30-14:45

POSTER DISCUSSION SESSION
Time: 14:00-18:00 [discussion 17:00-18:00]
Venue: E451a [E354b]

Lymphoma and plasma cell disorders

A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy (M Wang; Poster 5, Abstract 8030)

Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: Long-term follow-up of a phase II study (MJ Rummel; Poster 9, Abstract 8034)

Efficacy and toxicity of dose-adjusted EPOCH-rituximab in adults with newly diagnosed Burkitt lymphoma (K Dunlevy; Poster 10, Abstract 8035)

R-Dhaoox, high dose chemotherapy (HDC) and rituximab maintenance as salvage treatment in relapsed/refractory (R/R) follicular (F) and mantle cells (MC) lymphomas (NHL) (M Rupolo; Poster 11, Abstract 8036)
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy (D Villa; Poster 12, Abstract 8037)

Effect of addition of rituximab to CHOP on survival of patients in both the GCB and non-GCB subgroups of diffuse large B-cell lymphoma (K Fu; Poster 15, Abstract 8040)

Rituximab induces long-term remissions in patients with HIV-associated multicentric Castleman's disease (M Bower; Poster 24, Abstract 8049)
POSTER DISCUSSION SESSION
Time: 08:00-12:00 [discussion 11:00-12:00]
Venue: E451a [E354a]

Lung cancer II

Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Cancer (FA Shepherd; Poster 20, Abstract 7571)
Hotels

Chicago Marriott Downtown
Magnificent Mile
540 North Michigan Avenue,
Chicago, IL 60611
Tel: 312 836 0100; Fax: 312 836 6139
www.marriott.com
Breakfast: Ventoso, 06:00-11:00

Four Points by Sheraton
630 North Rush Street,
Chicago, IL 60611
Tel: 312 981 6600; Fax: 312 981 6622
www.fourpointschicago.com
Breakfast: Chicago’s Room, 4th floor,
Mon-Fri 06:30-10:00;
Sat/Sun 07:00-10:30

Four Seasons Hotel Chicago
120 East Delaware Place,
Chicago, IL 60611
Tel: 312 280 8800; Fax: 312 280 1748
www.fourseasons.com
Breakfast: Seasons, 06:30-10:00

Hilton Chicago
720 South Michigan Avenue,
Chicago, IL 60605
Tel: 312 922 4400; Fax: 312 922 5240
www.hilton.com
Breakfast: The Pavilion,
Mon-Fri 05:30-11:00;
Sat 05:30-12:00; Sun 05:30-14:00

Hotel Orrington
1710 Orrington Avenue,
Evanston, IL 60201
Tel: 847 866 8700; Fax: 847 866 8724
www.hotellorlington.com
Breakfast: The Globe Café,
1st floor, 06:00-09:00

House of Blues Hotel
333 North Dearborn Street,
Chicago, IL 60610
Tel: 312 245 0333; Fax: 312 923 2458
www.houseofblueshotel.com
Breakfast: Bin36,
Mon-Fri 06:30-10:00;
Sat/Sun 07:00-12:00

Hyatt Regency Chicago
151 East Wacker Drive,
Chicago, IL 60601
Tel: 312 565 1234; Fax: 312 565 4414
www.chicagoregency.hyatt.com
Breakfast: The Bistro at 151,
East Tower, Green Level, 06:00-11:00

Hyatt Regency McCormick Place
2233 South Martin Luther King
Drive, Chicago, IL 60616
Tel: 312 567 1234; Fax: 312 567 4000
www.mccormickplace.hyatt.com
Breakfast: Shor, Grand Concourse,
06:00-11:00

Palmer House Hilton
17 East Monroe Street,
Chicago, IL 60603
Tel: 312 726 7500; Fax: 312 917 1707
www.hilton.com
Breakfast: The Big Downtown,
lower level, 06:30-10:00

Ritz-Carlton Chicago
160 East Pearson Street,
Chicago, IL 60611
Tel: 312 266 1000; Fax: 312 266 1194
www.fourseasons.com
Breakfast: The Café, 06:30-11:00

Whitehall Hotel
105 East Delaware Place,
Chicago, IL 60611
Tel: 312 944 6300; Fax: 312 944 8552
www.thewhitehallhotel.com
Breakfast: Fornetto Mei,
1st floor, 07:00-11:00